Intellectual Property: HHS Reference No. E–736–2013/0—US Provisional. Application No. 61/888,706 filed 09 Oct 2013.

Licensing Contact: Kevin W. Chang, Ph.D.; 301–435–5018; *changke@mail.nih.gov*.

Collaborative Research Opportunity: The National Institute of Dental and Craniofacial Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Role of Novel Hepatitis Delta Virus Variant. For collaboration opportunities, please contact David W. Bradley, Ph.D. at *bradleyda@nidcr.nih.gov*.

Treating or Inhibiting JC Polyomavirus Infection and JC Polyomavirus-Associated Progressive Multifocal Leukoencephalopathy

Description of Technology: Available for licensing are novel findings to generate immune response to JC polyomavirus (JCV). An immunogenic composition with a single JCV subtype VP1 polypeptide generates neutralizing antibodies to all JCV subtypes, including JCV with variant VP1 polypeptides. The invention is useful for the prevention, treatment, or inhibition of JCV infection and JCV-associated pathologies, such as progressive multifocal leukoencephalopathy (PML).

Also available for licensing are techniques for identifying a subject at risk for developing PML, based on detecting the absence of JCV neutralizing antibodies in the subject.

Potential Commercial Applications:

- Pharmaceutical treatments of JC virus infection.
- Pharmaceutical treatments or prevention of PML.
- Prediction or early diagnosis of the development of PML.

Competitive Advantages:

- Generating an immune response to all JC virus subtypes utilizing a JC virus capsid polypeptide from a single subtype.
- No known methods for identifying a subject at risk for developing PML by detecting the absence of JC virus neutralizing antibodies in the subject.

Development Stage:

- Early-stage.
- In vitro data available.
- In vivo data available (animal).
- In vivo data available (human).

Inventors: Christopher B. Buck (NCI), Upasana Ray (NCI), and Diana V. Pastrana.

Publication: Buck CB. Developing vaccines against BKV and JCV. Presentation, 5th International Conference on Polyomaviruses and Human Diseases: Basic and Clinical Perspectives, Stresa, Italy, May 9–11, 2013. Abstract published online in June 2013 in J Neurovirol. 2013;19:307. [DOI 10.1007/s13365–013–0171–0].

Intellectual Property: HHS Reference No. E–549–2013/0—US Provisional. Application No. 61/919,043 filed 20 Dec 2013.

Licensing Contact: Patrick McCue, Ph.D.; 301–435–5560; *mccuepat@mail.nih.gov*.

Collaborative Research Opportunity: The National Cancer Institute, Laboratory of Cellular Oncology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize methods of treating JC polyomavirus-related disorders. For collaboration opportunities, please contact John D. Hewes, Ph.D. at *hewesj@mail.nih.gov*.

Therapeutic for Sickle Cell Disease and Beta Thalassemias

Description of Technology: Sickle-cell disease and beta thalassemia are among the most common hereditary blood disorders in the world. It has been shown that patients exhibit less severe symptoms of these disorders when they produce unusually high levels of fetal hemoglobin (HbF). HbF production, which normally shuts off after birth, has been considered as a viable treatment because of inability to form hemoglobin aggregates within red blood cells responsible for painful episodes in patients. Researchers at the National Institute of Diabetes and Digestive and Kidney Diseases have identified a method of regulating the expression of fetal hemoglobin in adult red blood cells. The lead inventor and colleagues have developed novel expression vectors designed to reactivate production of HbF proteins through increased erythroid-specific expression of Lin28 or decreased expression of Let-7 micro-RNAs. This technology could lead to development of multiple types of therapeutics that ameliorate or eliminate the pathologies associated with human sickle-cell anemia and beta thalassemia.

Potential Commercial Applications: *Ex vivo* and *in vivo* therapeutics for treatment of sickle-cell anemia and beta thalassemias.

Competitive Advantages:

- Amplification of HbF expression 10-fold higher than existing methods.
- Reduced production of symptom-associated adult hemoglobin.
- Regulation of Lin28 and Let-7 expression with no immunogenic effects.
- Potential for viral and non-viral gene delivery.
- Potential for Genome Editing Therapy.

Development Stage:

- Early-stage.
- In vitro data available.
- In vivo data available (animal).

Inventors: Jeffery L. Miller (NIDDK), Yuanwei T. Lee (NIDDK), Colleen Byrnes (NIDDK), Jaira Vasconcellos (NIDDK), Stefan A. Muljo (NIAID).

Publication: Lee YT, et al. LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. Blood. 2013 Aug 8;122(6):1034–41. [PMID 23798711].

Intellectual Property: HHS Reference No. E–456–2013/2—International. Application No. PCT/US2013/067811 filed 31 Oct 2013.

Licensing Contact: Vince Contreras, Ph.D.; 301–435–4711; *contrerasv@mail.nih.gov*.

Dated: April 14, 2014.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2014–08881 Filed 4–17–14; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Clinical Trials and Translational Research Advisory Committee.

Date: July 16, 2014.

Time: 9:00 a.m. to 4:00 p.m.

Agenda: Strategic Discussion of NCI's Clinical and Translational Research Programs.

Place: National Institutes of Health, Building 31, Room 10, 31 Center Drive, Bethesda, MD 20892.

Contact Person: Sheila A. Prindiville, MD, MPH, Director, Coordinating Center for

Clinical Trials, National Institutes of Health, National Cancer Institute, Coordinating Center for Clinical Trials, 9609 Medical Center Drive, Room 6W136, Rockville, MD 20850, 240–276–6173, *prindivs@mail.nih.gov*.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: *http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm,* where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 14, 2014.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2014–08883 Filed 4–17–14; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the NIH Scientific Management Review Board (SMRB). Presentations and discussions will address programs and activities to engage pre-college students in biomedical science as well as the NIH peer review and award processes.

The NIH Reform Act of 2006 (Public Law 109–482) provides organizational authorities to HHS and NIH officials to: (1) Establish or abolish national research institutes; (2) reorganize the offices within the Office of the Director, NIH including adding, removing, or transferring the functions of such offices or establishing or terminating such offices; and (3) reorganize, divisions, centers, or other administrative units within an NIH national research institute or national center including adding, removing, or transferring the functions of such units, or establishing or terminating such units. The purpose of the SMRB is to advise appropriate HHS and NIH officials on the use of these organizational authorities and identify the reasons underlying the recommendations.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Scientific Management Review Board (SMRB).

Date: May 7, 2014.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: Presentations and discussions at the May 7 SMRB meeting will focus on two recent SMRB charges: 1) Recommend ways for NIH to cultivate sustained interest in biomedical science among students from pre-kindergarten through high school in order to contribute to a healthy biomedical workforce pipeline, and 2) recommend ways for NIH to further optimize the process of reviewing and awarding grants. Time will be allotted on the agenda for public comment. Sign up for public comments will begin approximately at 8:00 a.m. on May 7, 2014, and will be restricted to one sign-in per person. In the event that time does not allow for all those interested to present oral comments, any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Place: National Institutes of Health, Building 35, 1th Floor, Porter Seminar Room, 9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Juanita Marner, Office of Science Policy, Office of the Director, NIH, National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, *smrb@mail.nih.gov,* (301) 435–1770.

This meeting is being published less than 15 days prior to the meeting due to scheduling conflicts of the members.

The meeting will be webcast. The draft meeting agenda and other information about the SMRB, including information about access to the webcast, will be available at *http://smrb.od.nih.gov*.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxis, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: April 15, 2014.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2014–08947 Filed 4–17–14; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel, Exceptional Unconventional Research Enabling Knowledge Acceleration, (EUREKA) for Neuroscience and Disorders of the Nervous System.

Date: May 5, 2014.

Time: 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: A. Roger Little, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6132, Bethesda, MD 20892–9609, 301–402–5844, *alittle@mail.nih.gov*.

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)